Evidence map›Paper›PMID 34746366›Full record

ArticleApplied materials today2020

Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer.

Ya Chang, Jizong Jiang, Wu Chen, Wen Yang, Lili Chen, Pengyu Chen, Jianzhong Shen, Shizhi Qian, Teng Zhou, Linfeng Wu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Applied materials today, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Comprehensive comparison of theranostic nanoparticles in breast cancer.American journal of clinical and experimental immunology · 2022
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ya Chang *Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, 36849, USA.
Jizong Jiang *State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Wu ChenDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, 36849, USA.
Wen YangMaterials Research and Education Center, Materials Engineering, Department of Mechanical Engineering, Auburn University, Auburn, AL, 36849, USA.
Lili ChenMaterials Research and Education Center, Materials Engineering, Department of Mechanical Engineering, Auburn University, Auburn, AL, 36849, USA.
Pengyu ChenMaterials Research and Education Center, Materials Engineering, Department of Mechanical Engineering, Auburn University, Auburn, AL, 36849, USA.
Jianzhong ShenDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, 36849, USA.
Shizhi QianDepartment of Mechanical and Aerospace Engineering, Old Dominion University, Norfolk, VA, 23529, USA.
Teng ZhouDepartment of Mechanical and Aerospace Engineering, Old Dominion University, Norfolk, VA, 23529, USA.
Linfeng WuCollege of Dentistry, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Liang HongCollege of Dentistry, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Yongzhuo HuangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Feng LiDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, 36849, USA.

Funding

Purchase of a modularized confocal microscopeR35GM133795 · NIGMS · AUBURN UNIVERSITY AT AUBURN · PI Pengyu Chen · 2019 to 2026
$3.3M
NIGMS NIH HHS R35 GM133795
6 · The paper itself

Abstract

Disulfiram (DSF) is currently tested in several clinical trials for cancer treatment in combination with copper (Cu) ions. Usually, DSF and Cu are administered in two separate formulations. In the body, DSF and Cu ions form diethyldithiocarbamate copper complex [Cu(DDC)

Indexed as

Biomimetic deliveryBreast cancerCopper diethyldithiocarbamateDisulfiramMetal-organic nanoparticleMicrofluidic

Identifiers

PMID34746366
PMCPMC8570539

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.